REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Results & Progress
7

Tirzepatide — 12 Week Progress Report

Arrow Jordan·about 2 months ago
Twelve weeks in with Tirzepatide and I wanted to give a thorough progress report. I have been tracking metrics closely since day one. The first noticeable change came around week 2-3: improved sleep quality. I went from waking up 2-3 times per night to sleeping through consistently. My sleep tracker confirmed what I was feeling — deep sleep increased by about 25 percent. By week 6, the recovery improvements were undeniable. Soreness after heavy training sessions dropped from 2-3 days to about 1 day. I was able to increase training frequency from 4 to 5 days per week without feeling overtrained. Body composition shifted gradually. I did not see dramatic scale changes, but my waist measurement dropped by about an inch while my weight stayed roughly the same. Clothes fit differently. A DEXA scan would have been nice but was not in my budget. Energy levels improved noticeably in the afternoon slump period. I used to rely on coffee around 2-3pm but have not needed it since about week 4. Overall I would rate Tirzepatide as genuinely effective for my goals. Not a miracle but a meaningful improvement across multiple health markers.

Comments (5)

Lee CunninghamDEMO·about 2 months ago

This thread has been incredibly helpful for understanding Tirzepatide. I have been on the fence about starting for months and reading detailed real-world experiences like these has been more useful than any blog post or article I have found. The fact that most reports here are moderate rather than extreme actually increases my confidence.

3
Gray ColemanDEMO·about 2 months ago

One thing I wish more Tirzepatide discussions covered is the discontinuation experience. What happens when you stop? In my case, the benefits gradually faded over about 3-4 weeks after stopping. Sleep was the first thing to return to baseline. Recovery improvements lasted a bit longer. Worth knowing for planning protocol duration.

4
Penn HarrisDEMO·about 2 months ago

Great point about bloodwork. I ran comprehensive panels at baseline, 6 weeks, and 12 weeks during my Tirzepatide protocol. The most informative markers for me were inflammatory markers and IGF-1 levels. Would strongly recommend anyone running Tirzepatide to invest in proper monitoring.

5
Crew HarrisDEMO·about 2 months ago

The timeline you describe is spot on with my Tirzepatide experience. I also want to emphasize the importance of injection technique. When I switched from 30-gauge to 29-gauge needles and slowed my injection speed, the site irritation essentially disappeared. Small details make a big difference in compliance.

2
Dylan HenryDEMO·about 2 months ago

Following up on my earlier comment about Tirzepatide. I am now 4 weeks past the end of my protocol and wanted to report that about 60 percent of the benefits seem to have persisted. Sleep is still better than baseline, recovery is somewhere between pre-protocol and on-protocol levels. Encouraging for the sustainability question.

3

Sign in to comment.